Opthea Limited (AU:OPT) has released an update.
Opthea Limited has appointed Kathy Connell as a Non-Executive Director to its Board, bringing her extensive experience in business development to aid the company’s strategic growth. This move comes as Opthea gears up for a crucial Phase 3 data release of its treatment for wet age-related macular degeneration (wet AMD). Connell’s expertise is expected to enhance shareholder value and drive Opthea’s success in the competitive biopharmaceutical sector.
For further insights into AU:OPT stock, check out TipRanks’ Stock Analysis page.
